Aimmune Therapeutics

Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Shift4 Payments

These under-the-radar names pack some huge growth potential.

Got $2,000? Investing in These 3 Small-Cap Stocks Can Make You Rich

Aimmune Therapeutics may be struggling now in the Best Stocks contest, but the future is still bright for AIMT stock thanks to Palforzia.
The post Best Stocks for 2020: Expect Aimmune Stock to Come Back in Full Force appeared first on InvestorPlace.

Best Stocks for 2020: Expect Aimmune Stock to Come Back in Full Force

Armed with the recent approval of Palforzia, the first FDA-approved treatment for peanut allergy, could Aimmune Therapeutics turn things around?

Down 40% in 6 Months, Is Aimmune Therapeutics a Buy?

Aimmune Shares Look Cheap On A Discounted Cash Flow Basis

Short-sellers are convinced a company marketing the first approved biologic for treating peanut allergies in children and teenagers will fail. Here's why.

Why Are So Many Traders Betting Against the First Therapy for Peanut Allergies?

Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q1 2020 Results - Earnings Call Transcript

Aimmune Therapeutics (AIMT) delivered earnings and revenue surprises of 10.44% and -67.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Aimmune Therapeutics (AIMT) Reports Q1 Loss, Misses Revenue Estimates

DBV Technologies SA Sponsored ADR

Aimmune Therapeutics Beats DBV Technologies In Multi-Billion Dollar Market To Treat Peanut Allergies

DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.

A Tale of 2 Biotechs With Competing Peanut Allergy Treatments

Epizyme

Esperion Therapeutics

Horizon Pharma

These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.

Should You Buy These 4 Biotech Stocks With Recent Drug Approvals?

Apple

Disney

Energy Transfer LP Unit

Freeport-McMoRan

Hercules Capital

 Luckin Coffee

PennyMac Financial Services

Roku

Wayfair

InvestorPlace's Best Stocks for 2020 contest looks dismal after Q1. What will happen with the pandemic, and which stock will win?

10 Best Stocks for 2020: Get Ready for a Roller Coaster Ride in Q2

Aimmune: On Sale After Coronavirus Crash

Aimmune Therapeutics received FDA approval for its Palforzia, so AIMT stock will still be one of the best stocks in 2020. 
The post Best Stocks for 2020: Aimmune Therapeutics Will Rebound on FDA Approval appeared first on InvestorPlace.

Best Stocks for 2020: Aimmune Therapeutics Will Rebound on FDA Approval

A risk management process slowed the launch of Aimmune’s first product.

Why Aimmune Therapeutics Shares Fell 23.3% in February

Allergies are a big problem in the world today. Some consumers have made a choice to avoid certain foods or avoid certain ingredients, but some people literally have to avoid certain things at the risk of inflammation, serious illness or even death.

One Call Still Sees a Double-Your-Money Upside from the Peanut Allergy Treatment

A month after the drug's approval, Aimmune is still working on getting it to patients.

Aimmune's Launch of Peanut Allergy Drug Will Take Time

Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q4 2019 Results - Earnings Call Transcript

Investors need to pay close attention to Aimmune (AIMT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Aimmune (AIMT) Stock?

Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.

What's in Store for Aimmune (AIMT) This Earnings Season?

Aimmune Therapeutics (AIMT) closed at $29.17 in the latest trading session, marking a -1.12% move from the prior day.

Aimmune Therapeutics (AIMT) Stock Sinks As Market Gains: What You Should Know

Aimmune Proves Its Worth With Latest FDA Approval; Other Candidates Left To Advance

The food allergy specialist just landed its first approval.

Aimmune Therapeutics Just Made History: Is It a Buy?

Nestle SA

Aimmune Therapeutics Inc (NASDAQ: AIMT) recently received FDA approval for its peanut allergy drug Palforzia.

Aimmune Analyst Says Palforzia Launch Funding Secured With Nestle's $200M Investment

Aimmune Therapeutics received FDA approval for its peanut allergy drug Palforzia, and AIMT stock could soar in 2020.
The post Aimmune’s Prospects Shine After the FDA Approves Its Allergy Drug appeared first on InvestorPlace.

Aimmune’s Prospects Shine After the FDA Approves Its Allergy Drug

Another $200 million investment from Nestle will turbocharge Palforzia's commercial launch.

News for Aimmune Therapeutics Stock (AIMT)